Before-surgery chemotherapy for locally advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests chemotherapy given before surgery (called FOLFIRINOX) for people with locally advanced stomach cancer. The goal is to shrink the tumor and improve outcomes after the surgery plan is completed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach adenocarcinoma (a specific stomach cancer type) that the team believes can be removed with surgery.
- Your cancer has “locally advanced” features (like deeper tumor growth and/or nearby lymph node involvement), but you do not have distant spread (no metastases).
- You are age 18 to 75 and can do daily activities at a good level (ECOG 0 to 1).
- Your kidneys and liver tests are within required limits (kidney filtering above 50 mL/min, and certain blood tests not too high).
- You have not had prior chemotherapy or radiation for this cancer, and you are not currently pregnant or breastfeeding.
- You can meet the study schedule and follow-up, and you do not have certain other serious medical or mental health conditions that would interfere with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four chemotherapy drugs (irinotecan liposome, 5-FU + leucovorin, oxaliplatin, and Karelizumab) given before surgery to shrink stomach cancer. The goal is to see if this combination makes the cancer easier to remove and improves outcomes.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.